Catalyst Dossier · compiled by CeliA 🧫

Sanofi (SNY)

Pharmaceutical Preparations · market cap $100.0B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-06-29 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Sanofi (SNY) is a French multinational pharmaceutical company with a ~$100B market cap, trading at ~$41.78 on Nasdaq, and a broad pipeline spanning immunology, hematology, vaccines, and metabolic diseases. The near-term catalyst slate is dense, headlined by a Phase 3 readout for amlitelimab (est. June 29) and fitusiran (est. November 5), both rated high importance. A PDUFA approval was recorded on June 16, though the specific asset approved is not identified in available data.

The catalyst path

2026-06-29 (est.)Phase 3 · Amlitelimabimp 9/10
2026-07-10 (est.)Phase 2 · SAR441344 IVimp 7/10
2026-07-30Earningsimp 5/10
2026-08-04 (est.)Phase 2 · Amlitelimabimp 7/10
2026-08-25 (est.)Phase 2 · Rilzabrutinib dose 1imp 7/10
2026-08-31 (est.)Phase 2 · Belumosudilimp 7/10
2026-11-05 (est.)Phase 3 · Fitusiranimp 9/10
2026-11-06 (est.)Phase 2 · Mometasone furoate nasal spray (MFNS)imp 7/10

Pipeline

Asset	Phase	Indication
SR147778	Phase 2	Obesity
XRP0038 (NV1FGF)	Phase 2	Peripheral Arterial Disease
efanesoctocog alfa (BIVV001)	Phase 3	Hemophilia A
Duvakitug	Phase 3	Ulcerative Colitis
xaliproden (SR57746A)	Phase 3	Alzheimer Disease
zolpidem-MR (SL800750)	Phase 3	Sleep Initiation and Maintenance Disorders
A/H1N1 pandemic influenza vaccine (non- adjuvanted)	Phase 3	Influenza
CYD dengue vaccine serotypes (1, 2, 3, 4).	Phase 2	Dengue Virus
lactoserum	Phase 3	Hygiene
Docetaxel	Phase 3	Stomach Neoplasms
DTaP-IPV-HB-PRP~T	Phase 3	Diphtheria
Yellow fever vaccine (live)	Phase 3	Yellow Fever Immunization
G-CSF Plus Plerixafor	Phase 2	Hodgkin's Disease
SAR443122	Phase 2	Colitis Ulcerative
Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus	Phase 3	Dengue
epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile	Phase 3	Breast Neoplasms
Low Dose (LD) RSVt vaccine	Phase 3	RSV Immunisation
Insulin glargine/lixisenatide fixed ratio combination	Phase 3	Type 2 Diabetes Mellitus
RSV vaccine candidate	Phase 2	Respiratory Syncytial Virus Infection
Fexofenadine	Phase 3	Seasonal Allergic Rhinitis

Price & technical context

3-month

-7.1%

6-month

-13.3%

12-month

-14.1%

52-wk range

$41.60–$52.34

vs 50-day MA

-6.6%

vs 200-day MA

-11.7%

Realized vol

27.4%

Max drawdown

-30.0%

Daily closes through 2026-06-23. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SNY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.